Chimeric small molecules for the recruitment of antibodies to cancer cells
AssigneeYale University
InventorsDavid Spiegel, Ryan Murelli, Andrew Zhang
Life of this patent
Estimating the term…
Abstract
The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.
Claims30
A composition in pharmaceutical dosage form in combination with a pharmaceutically acceptable carrier, additive or excipient, comprising an anticancer effective amount of a compound according to the chemical structure:
- Wherein each n is independently 1 or 2;
- A is an antibody binding moiety according to the chemical structure:
- Where Y′ is H or NO2;
- X is O, CH2, NR1, S(O), S(O)2, —S(O)2O, —OS(O)2, or OS(O)2O;
- R1 is H, a C1-C3 alkyl group, or a —C(O)(C1-C3) group;
- Xb is a bond, O, CH2, NR1 or S;
- B is a cell binding moiety according to the chemical formula:
- Wherein X1 and X2 are each independently CH2, O, NH or S;
- X3 is O, CH2, NR1, S(O), S(O)2, —S(O)2O, —OS(O)2, or OS(O)2O;
- R1 is H, a C1-C3 alkyl group, or a —C(O)(C1-C3) group;
- k is an integer from 1 to 10;
- L is a linker according to the chemical formula:
- Or L is a polyethylene glycol, polypropylene glycol or polypropylene-co-polyethylene glycol linker having between 1 and 20 glycol units;
- Wherein Ra is H, C1-C3 alkyl or alkanol or together with Ra forms a proline side chain with R3;
- R3 forms a proline side chain with Ra or R3 is a side chain derived from an amino acid selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan and valine;
- and
- Each m is independently an integer from 1 to 12;
- or
- L is a linker according to the chemical formula:
- Where Z and Z′ are each independently a bond, —(CH2)i-O, —(CH2)i-S, —(CH2)i-N-R,
- wherein said —(CH2)i group, if present in Z or Z′, is bonded to[CON], antibody binding terminus (ABT) or cell binding terminus (CBT);
- Each R is independently H, or a C1-C3 alkyl or alkanol group;
- Each R2 is independently H or a C1-C3 alkyl group;
- Each Y is independently a bond, O, S or N-R;
- Each i is independently an integer from 0 to 15;
- D is
- or a bond,
- with the proviso that Z, Z′ and D are not each simultaneously bonds;
- j is an integer from 1 to 100;
- m′ is an integer from 1 to 100;
- n′ is an integer from 1 to 100;
- and
- X″ is O, S or N-R,
- R is as defined above;
- and
- [CON] is a bond or a moiety according to the chemical structure:
- Where X2 is O, S, NR4, S(O), S(O)2, —S(O)2O, —OS(O)2, or OS(O)2O;
- X3 is NR4, O or S;
- and R4 is H, a C1-C3 alkyl or alkanol group, or a —C(O)(C1-C3) group;
- or
- a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.